Company intelligence / Profile preview
Zerion Pharma
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
Overview
Zerion Pharma develops proprietary formulations using its Dispersome® platform to improve the solubility, bioavailability, and patient convenience of poorly soluble oral drugs. The company partners with major pharma firms for both marketed products and new chemical entities. Its first cannabidiol formulation was set to enter clinical trials in 2024. In collaboration with Aché Laboratorios Farmacêuticos S.A., it aims to reformulate billion-dollar revenue drugs in oncology and neuroscience for improved patient outcomes.
- Therapeutic areas
- OncologyNeurologyOther
- Modalities
- Small molecules (focus on poorly soluble small molecule drugs)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Zerion Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zerion Pharma.